Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Leukemia, Myeloid, Acute 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Cancer Resectable 1Ovarian Carcinosarcoma 1Noonan Syndrome 5 1Neoplasms, Second Primary 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Monocytic, Acute 1Leukemia, Lymphoid 1Immune-related Adverse Event 1Esophageal Neoplasms 1Early Hormone Receptor-positive Breast Cancer 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1Advanced Ovarian Cancer 1

Interventions

Saline Solution 3Carboplatin 2Bevacizumab 2talazoparib 1stenoparib 1senaparib 1sargramostim 1olaparib 1liposomal doxorubicin 1Tranexamic Acid 1Ropivacaine 1Paclitaxel 1Neoadjuvant Therapy 1Antineoplastic Agents 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Ovarian Cancer × Antineoplastic Agents × Clear all
NCT03611179 2018-08-02

Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer

Assiut University

Phase 2 Unknown
40 enrolled
Gynecologic

Advanced Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡